THE EFFECT ON THE HUMAN UTERUS OF TWO NEWLY DEVELOPED COMPETITIVE INHIBITORS OF OXYTOCIN AND VASOPRESSIN

@article{kerlund1985THEEO,
  title={THE EFFECT ON THE HUMAN UTERUS OF TWO NEWLY DEVELOPED COMPETITIVE INHIBITORS OF OXYTOCIN AND VASOPRESSIN},
  author={Mats {\AA}kerlund and Anita Carlsson and Per Melin and Jerzy Andrzej Trojnar},
  journal={Acta Obstetricia et Gynecologica Scandinavica},
  year={1985},
  volume={64}
}
Abstract. in order to develop inhibitors of vasopressin (VP) and oxytocin (OXY) action on uterine activity, 1‐deaminat‐ed vasotocin derivatives with modifications at positions 2, 4 and 8 were developed. Two of the most effective analogues in the rat, l‐deamino‐2‐D‐Tyr(OEt)‐4‐Val‐8‐Orn‐vasotocin (dE‐VVT) and l‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐vaso‐tocin (dE‐TVT) were now tested on human nonpregnant myometrium obtained at hysterectomy in fertile age and on pregnant myometrial tissue obtained at… 
Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women
Summary. Three analogues of posterior pituitary hormones, 1 ‐ deamino ‐ 2 ‐ D ‐ Tyr(OEt) ‐ 4 ‐ Val ‐ 8 ‐ Om ‐ vasotocin(dE ‐ VVT), l‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐vasotocin(dE‐TVT) and
Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot study
TLDR
The results of this preliminary study support the concept of an increased concentration of uterine oxytocin receptors being aetiologically important in uncomplicated premature labour and suggest that the present Oxytocin antagonist could be an interesting therapeutic alternative in the condition, primarily because of the marked selectivity of its effect.
The development and introduction of anti‐oxytocic tocolytics
  • R. Lamont
  • Medicine, Biology
    BJOG : an international journal of obstetrics and gynaecology
  • 2003
TLDR
Atosiban was found to be at least as effective as the beta‐agonists as a tocolytic agent, but significantly less likely to result in maternal cardiovascular side effects or the need to discontinue therapy as a result of unacceptable side effects.
Effects of oxytocin antagonist (dTVT) and ritodrine on spontaneous and oxytocics-induced uterine contractions in pregnant rats.
  • T. Chimura
  • Biology, Medicine
    Asia-Oceania journal of obstetrics and gynaecology
  • 1991
TLDR
DTVT treatment did not affect spontaneous PGE2- or PGF2 alpha-stimulated contraction, while it slightly suppressed PGE1 analogue (Gemeprost)- Stimulated contraction of the uterus, and ritodrine treatment rapidly suppressed spontaneous uterine contraction as well as contraction stimulated by various oxytocics.
Oxytocin receptor blockade and prostaglandin release in late pregnant sheep.
FE 200 440: a selective oxytocin antagonist on the term‐pregnant human uterus
TLDR
A newly developed oxytocin antagonist, FE 200 440, with atosiban and ANTAG III, is compared as to potency and selectivity of inhibitory effects on Oxytocin‐ and vasopressin‐induced myometrial responses.
Vasopressin and oxytocin in normal reproduction and in the pathophysiology of preterm labour and primary dysmenorrhoea. Development of receptor antagonists for therapeutic use in these conditions.
  • M. Åkerlund
  • Medicine, Biology
    Roczniki Akademii Medycznej w Bialymstoku
  • 2004
TLDR
In the onset of labour preterm and at term pregnancy vasopressin and oxytocin are centrally involved and in primary dysmenorrhoea the former hormone seems to play a key role in the mechanisms of increased contractions and reduced blood flow in the uterus of the condition.
...
...

References

SHOWING 1-10 OF 12 REFERENCES
Vasopressin effects on isolated non‐pregnant myometrium and uterine arteries and their inhibition by deamino‐ethyl‐lysine‐vasopressin and deamino‐ethyl‐oxytocin
TLDR
The inhibition of the myometrial and uterine artery responses to AVP could explain the therapeutic effect of dE‐OXY recently found in primary dysmenorrhoea, where increased VP secretion seems to be of aetiological importance.
Synthetic antagonists of the myometrial response to vasopressin and oxytocin.
TLDR
In myometrium from non-pregnant women the inhibitory effects of the majority of the analogues were less pronounced and the most potent peptide was 1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin, which was 2.0 times more potent that d(OET)-oxytOCin.
Inhibition of vasopressin effects on the uterus by a synthetic analogue.
TLDR
It is suggested that deamino-ethyl-oxytocin could be of therapeutic value in primary dysmenorrhea, a condition associated with increased vasopressin secretion.
Inhibitory effect of O-alkylated analogues of oxytocin and vasopressin on human and rat myometrial activity.
Analogues of oxytocin and vasopressin modified through O-alkylation (methyl, ethyl and butyl) at position 2 of the peptide chain were synthesized and tested for effects on the rat uterus in vivo and
Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor.
TLDR
In vitro, prostaglandin production by the decidua, but not by the myometrium, was increased by the addition of oxytocin, and Oxytocin may stimulate uterine contractions by acting both directly on theMyometrium and indirectly on decidual prostaglandsin production.
Vasopressin and Prostaglandins in Premenstrual Pain and Primary Dysmenorrhea
TLDR
It is concluded that the pathophysiology of premenstrual pain could imply increased vasopressin secretion, and the more severe pain in primary dysmenorrhea seems to be the result of a combined effect of vasoppressin and PGF2alpha.
PRIMARY DYSMENORRHOEA AND VASOPRESSIN
TLDR
The results suggest that vasopressin could be a factor of aetiological importance in primary dysmenorrhoea, and also indicate that the vasoppressin concentration in plasma can vary according to the day of the menstrual cycle.
Neurohypo - physial peptides . Design of tissue - specific agonists and antagonists
  • Molec Cell Endocrinol
  • 1981
Synthetic antagonists of the myometrial response to oxytocin and vasopressin. Endocrinol (su6-mitted for publication
    ...
    ...